COGT Live signaler | Maksimer profitt med Getagraph.com

SELG 104768 min ago

@ $8.60

Utstedt: 14 feb 2024 @ 21:09

Avkastning: -30.00%

Forrige signal: feb 14 - 18:47

Forrige signal: Kjøp

Avkastning: -2.05 %

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Stats
Dagens volum	912 095
Gjennomsnittsvolum	2.15M
Markedsverdi	575.59M
EPS	$0 ( 2024-03-12 )
Neste inntjeningsdato	( $-0.500 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.49
ATR14	$0.00500 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Ferrante Karen Jean	Buy	3 213	Stock Option (Right to Buy)
2024-03-28	Fairmount Funds Management Llc	Buy	286 851	Common Stock
2024-03-28	Fairmount Funds Management Llc	Buy	11 914	Series A Convertible Preferred Stock
2024-03-28	Fairmount Funds Management Llc	Sell	11 914	Series A Convertible Preferred Stock
2024-03-28	Fairmount Funds Management Llc	Sell	286 851	Common Stock

INSIDER POWER
88.06
Last 97 transactions
Buy: 19 542 341 \| Sell: 1 316 263

Volum Korrelasjon

Lang: -0.11 (neutral)

Kort: -0.48 (neutral)

Signal:(56.59) Neutral

Cogint Inc. Korrelasjon

10 Mest positive korrelasjoner
NWL	0.911
CPIX	0.903
PRAX	0.9
CNDT	0.891
EWTX	0.89
QMCO	0.887
AQB	0.886
AVDX	0.886
SRTS	0.885
CHB	0.885

10 Mest negative korrelasjoner
PPBT	-0.881
FIZZ	-0.864
EPZM	-0.833
SNCR	-0.822
XOG	-0.821
TYHT	-0.816
LEDS	-0.805

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Cogint Inc. Korrelasjon - Valuta/Råvare

-0.17
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.44
( neutral )

Cogint Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-3.59M (0.00 %)
EPS:	$-2.42

FY	2023
Omsetning:	$0
Bruttogevinst:	$-3.59M (0.00 %)
EPS:	$-2.42

FY	2022
Omsetning:	$0
Bruttogevinst:	$-5.88M (0.00 %)
EPS:	$-2.26

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.814

Financial Reports:

No articles found.

Cogint Inc.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.